Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
TransPharma Medical logo — Pioneering transdermal drug delivery to enhance therapeutic...

TransPharma Medical

Pioneering transdermal drug delivery to enhance therapeutic outcomes for osteoporosis and other peptide-based treatments.

Founded 2000 Series C Total: $33.40M Biotechnology, Health Care +1

General Information

Company Name TransPharma Medical
Founded Year 2000
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Series C
Social

BounceWatch is an independent company data service, not affiliated with TransPharma Medical. To contact TransPharma Medical, visit transpharma-medical.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does TransPharma Medical compare?

A PDF of TransPharma Medical and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting TransPharma Medical soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About TransPharma Medical

TransPharma Medical Ltd. is a specialty pharmaceutical company founded in 2000, with a focus on transdermal drug delivery technology. Their flagship product, ViaDerm-hPTH (1-34), designed for treating osteoporosis, is currently undergoing Phase 2B clinical trials in collaboration with Eli Lilly. In addition to this groundbreaking product, the company is also advancing two other peptide-based treatments through Phase 1 trials. The company's commitment to advancing therapeutic outcomes for osteoporosis and other peptide-based treatments is encapsulated in their slogan: "Pioneering transdermal drug delivery to enhance therapeutic outcomes for osteoporosis and other peptide-based treatments." In July 2006, TransPharma Medical secured an $18.00M Series C investment from a consortium of prominent investors, including Pitango Venture Capital, Argonaut Private Equity, Evergreen Venture Partners, Biomedical Investments, Teva Pharmaceuticals, TIF Ventures Pte, and T2C2 Capital. With its innovative technology and promising product pipeline, TransPharma Medical represents an exciting opportunity in the biotechnology, healthcare, and pharmaceutical sectors for potential investors.

Business keywords: transdermal drug delivery, osteoporosis treatment, peptide-based treatments, pharmaceutical company, drug-product development, active transdermal technology, clinical trials, proprietary drug development, specialty pharmaceuticals, Phase 2B trials, Phase 1 trials, innovative drug delivery, collaboration with Eli Lilly, therapeutic outcomes, specialty pharmaceutical development

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series C $18.00M 7
Pitango Venture Capital Argonaut Private Equity Evergreen Venture Partners
Pitango Venture Capital, Argonaut Private Equity +5
24 Jul 2006
Series B $8.90M 3
Pitango Venture Capital Evergreen Venture Partners Biomedical Investments
Pitango Venture Capital, Evergreen Venture Partners +1
18 Jan 2003
Series A $6.50M -
01 Jan 2001

TransPharma Medical Alternatives & Competitors

View All Alternatives
TransPharma Medical vs
Corium International
Corium International

Harnessing proprietary technologies to advance transdermal drug delivery for enhanced therapeutic ou...

Debt Financing
201-500 employees
Biotechnology, Health Care
TransPharma Medical vs
BBB Therapeutics
BBB Therapeutics The Netherlands

Combines existing drugs with it's proprietary for enhanced drug delivery across the blood-brain barr...

21 employees
Biopharma, Biotechnology
TransPharma Medical vs
Noven Pharmaceuticals
Noven Pharmaceuticals United States

A fully-integrated specialty pharmaceutical company with industry-leading transdermal expertise

941 employees
Biotechnology, Health Care
View all alternatives

FAQ About TransPharma Medical

Pioneering transdermal drug delivery to enhance therapeutic outcomes for osteoporosis and other peptide-based treatments.
TransPharma Medical was founded in 2000.
TransPharma Medical operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on transdermal drug delivery, osteoporosis treatment, peptide-based treatments and pharmaceutical company.
TransPharma Medical has completed 3 funding rounds, raising a total of $33.40M. The latest funding stage is Series C.
Top alternatives and competitors to TransPharma Medical include Corium International, BBB Therapeutics, Noven Pharmaceuticals, SciTech Development, Inc., VG Life Sciences. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
TransPharma Medical and Corium International are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for TransPharma Medical, https://bouncewatch.com/company/transpharma-medical, updated 26 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout